Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Renal Insufficiency, Chronic

ClinicalTrials.gov lists 4,731 trials for Renal Insufficiency, Chronic or a narrower condition beneath it. Amgen has the most among industry and government lead sponsors, with 68.

MeSH D051436 Urogenital Diseases C12 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 300 Phase 1/2 Phase 1/2 92 Phase 2 Phase 2 434 Phase 2/3 Phase 2/3 64 Phase 3 Phase 3 437 Phase 4 Phase 4 517 Not applicable Not applicable 1,657 Observational Observational 1,225 Phase 1 Phase 1 300 Phase 1/2 Phase 1/2 92 Phase 2 Phase 2 434 Phase 2/3 Phase 2/3 64 Phase 3 Phase 3 437 Phase 4 Phase 4 517 Not applicable Not applicable 1,657 Observational Observational 1,225

Trials per phase (log scale)

1 more section with rows

3,064 of the 4,731 trials are tagged with Renal Insufficiency, Chronic itself; the rest are tagged with a narrower condition beneath it.

Get the Renal Insufficiency, Chronic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Renal Insufficiency, Chronic trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 13 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 292

1991: 1 trials (Observational 1) 1992: 1 trials (Observational 1) 1993: 2 trials (Observational 1, Phase 2 1) 1994: 1 trials (Observational 1) 1995: 4 trials (Not applicable 2, Phase 3 1, Phase 2 1) 1996: 4 trials (Observational 2, Not applicable 2) 1997: 6 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 2) 1998: 6 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 2) 1999: 7 trials (Not applicable 3, Phase 3 4) 2000: 14 trials (Observational 10, Not applicable 2, Phase 3 2) 2001: 22 trials (Observational 6, Not applicable 2, Phase 4 6, Phase 3 3, Phase 2 2, Phase 1 3) 2002: 36 trials (Observational 2, Not applicable 5, Phase 4 14, Phase 3 7, Phase 2/3 1, Phase 2 7) 2003: 41 trials (Observational 9, Not applicable 3, Phase 4 13, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 6) 2004: 71 trials (Observational 17, Not applicable 14, Phase 4 17, Phase 3 13, Phase 2/3 2, Phase 2 5, Phase 1/2 2, Phase 1 1) 2005: 96 trials (Observational 13, Not applicable 22, Phase 4 21, Phase 3 16, Phase 2/3 2, Phase 2 17, Phase 1/2 2, Phase 1 3) 2006: 119 trials (Observational 31, Not applicable 15, Phase 4 22, Phase 3 15, Phase 2/3 3, Phase 2 22, Phase 1/2 3, Phase 1 8) 2007: 115 trials (Observational 23, Not applicable 24, Phase 4 15, Phase 3 24, Phase 2/3 7, Phase 2 11, Phase 1/2 2, Phase 1 9) 2008: 158 trials (Observational 45, Not applicable 39, Phase 4 34, Phase 3 14, Phase 2/3 3, Phase 2 16, Phase 1/2 1, Phase 1 6) 2009: 160 trials (Observational 35, Not applicable 33, Phase 4 32, Phase 3 26, Phase 2/3 4, Phase 2 20, Phase 1/2 3, Phase 1 7) 2010: 182 trials (Observational 55, Not applicable 31, Phase 4 29, Phase 3 23, Phase 2/3 6, Phase 2 25, Phase 1/2 3, Phase 1 10) 2011: 182 trials (Observational 56, Not applicable 44, Phase 4 22, Phase 3 19, Phase 2/3 5, Phase 2 16, Phase 1/2 6, Phase 1 14) 2012: 173 trials (Other 1, Observational 37, Not applicable 52, Phase 4 25, Phase 3 24, Phase 2/3 1, Phase 2 21, Phase 1/2 3, Phase 1 9) 2013: 203 trials (Other 1, Observational 34, Not applicable 67, Phase 4 30, Phase 3 24, Phase 2/3 1, Phase 2 22, Phase 1/2 4, Phase 1 20) 2014: 206 trials (Observational 46, Not applicable 74, Phase 4 13, Phase 3 14, Phase 2/3 3, Phase 2 28, Phase 1/2 12, Phase 1 16) 2015: 220 trials (Observational 46, Not applicable 86, Phase 4 27, Phase 3 22, Phase 2/3 2, Phase 2 16, Phase 1/2 5, Phase 1 16) 2016: 207 trials (Observational 49, Not applicable 82, Phase 4 22, Phase 3 18, Phase 2/3 2, Phase 2 23, Phase 1/2 1, Phase 1 10) 2017: 195 trials (Observational 42, Not applicable 94, Phase 4 16, Phase 3 16, Phase 2/3 1, Phase 2 13, Phase 1/2 3, Phase 1 10) 2018: 207 trials (Observational 51, Not applicable 91, Phase 4 22, Phase 3 20, Phase 2/3 1, Phase 2 13, Phase 1/2 2, Phase 1 7) 2019: 245 trials (Observational 68, Not applicable 96, Phase 4 21, Phase 3 15, Phase 2/3 3, Phase 2 21, Phase 1/2 2, Phase 1 19) 2020: 168 trials (Observational 48, Not applicable 73, Phase 4 13, Phase 3 10, Phase 2 13, Phase 1/2 1, Phase 1 10) 2021: 263 trials (Observational 82, Not applicable 101, Phase 4 14, Phase 3 13, Phase 2/3 4, Phase 2 25, Phase 1/2 3, Phase 1 21) 2022: 257 trials (Observational 83, Not applicable 95, Phase 4 14, Phase 3 23, Phase 2/3 3, Phase 2 17, Phase 1/2 5, Phase 1 17) 2023: 256 trials (Observational 75, Not applicable 106, Phase 4 17, Phase 3 16, Phase 2/3 3, Phase 2 18, Phase 1/2 4, Phase 1 17) 2024: 281 trials (Observational 83, Not applicable 115, Phase 4 22, Phase 3 16, Phase 2/3 4, Phase 2 17, Phase 1/2 6, Phase 1 18) 2025: 292 trials (Observational 82, Not applicable 134, Phase 4 15, Phase 3 16, Phase 2/3 1, Phase 2 16, Phase 1/2 13, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 282
2025 292
2024 281
2023 256
2022 257
2021 263
2020 168
2019 245
2018 207
2017 195

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 320 trials starting in 2026 and about 310 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 340 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 2,949 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Renal Insufficiency, Chronic trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 300
Phase 1/2 92
Phase 2 434
Phase 2/3 64
Phase 3 437
Phase 4 517
Not applicable 1,657
Observational 1,225
Expanded access 5

How many Renal Insufficiency, Chronic trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 245
Recruiting 477
Enrolling by invitation 48
Active, not recruiting 182
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Renal Insufficiency, Chronic trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Amgen 68
Bayer 54
AstraZeneca 53
Vantive Health LLC 34
VA Office of Research and Development 28

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Renal Insufficiency, Chronic? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
EPOETIN ALFA 53
Finerenone 39
BMS-512148 38
Cinacalcet 33
Roxadustat 26

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
darbepoetin alfa SF 54
Paricalitol 45
IR Tacrolimus 33
Empagliflozine 30
Exercise 23

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Renal Insufficiency, Chronic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 3,724 213
Hospitalizations 2,405 4
Other 2,051 4
End stage renal disease 1,851 41
Sepsis 1,695 148

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Renal Insufficiency, Chronic? (2,913)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nature medicine 2026 Yes
REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney international 2026 Yes
Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function. Journal of diabetes and its complications 2026 Yes
Physical Activity and Exercise for Cardiometabolic Health and Fitness in CKD: An Overview by Exercise Type. Clinical journal of the American Society of Nephrology : CJASN 2026 Yes
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis. JAMA 2026 Yes

Showing 5 of 2,913 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages